Evacetrapib is an investigational cholesteryl ester transfer protein (CETP) inhibitor that was extensively researched as a therapeutic candidate for managing dyslipidemia, hyperlipidemia, and various cardiovascular… Read more
Evacetrapib is an investigational cholesteryl ester transfer protein (CETP) inhibitor that was extensively researched as a therapeutic candidate for managing dyslipidemia, hyperlipidemia, and various cardiovascular conditions. Although clinical trials demonstrated that the compound could modulate lipid profiles by increasing high-density lipoprotein and decreasing low-density lipoprotein, it did not provide the expected clinical benefit in reducing cardiovascular events and did not receive regulatory approval. This category includes essential reference standards for the Evacetrapib API, alongside a selection of its known impurities, metabolites, and stable isotope-labelled compounds. These analytical materials are critical for pharmaceutical laboratories engaged in impurity profiling, method validation, and routine quality control during research. By providing reliable, high-quality standards, these tools enable accurate identification and quantitative analysis of the drug and its related substances in complex analytical matrices.